Class III · Low risk
Verapamil Hydrochloride Injection
Cross contamination with other products.
Is Verapamil recalled?
Yes — there is an active recall. 3 ongoing FDA recalls mention Verapamil (17 total). Check the affected lots below.
Most common reason: Sterility / contamination (5 of these recalls)
Recalls are matched by product description. A recall usually affects specific lots, not every package of Verapamil. “Active” means an FDA recall is still ongoing; “closed” means it was terminated or completed. Checked against openFDA on Oct 10, 2026.
Verapamil recalls on record
none so far in 2026; 17 on record, newest first
Class III · Low risk
Verapamil Hydrochloride Injection
Cross contamination with other products.
Class III · Low risk
Trandolapril and Verapamil Hydrochloride Extended-Release Tablets 2 mg / 180 mg
Subpotent: Out of Specification for Assay Test at the 3-month time point.
Class II · Moderate risk
Verapamil Hydrochloride Extended-Release Tablets
Failed Dissolution Specifications: Out of specification dissolution results above specified values.
Class II · Moderate risk
Verapamil Hydrochloride Extended-Release Tablets
Failed Dissolution Specification: Out of specification dissolution results at time point zero. The OOS was above specified values.
Class II · Moderate risk
Verapamil HCL
cGMP deviations: Temperature abuse
Class II · Moderate risk
Verapamil Hydrochloride Extended-Release Tablets USP 120 mg Rx…
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Class II · Moderate risk
C-Verapamil 2.5mg/Ml Inj Soln
Lack of Assurance of Sterility: product sterility cannot be guaranteed.
Class II · Moderate risk
Verapamil HCl USP for prescription compounding
CGMP Deviations: Lack of stability data and controls to support the manufacturers assigned retest or expiration date in firm's container/closure system.
Class II · Moderate risk
Verapamil 120mg/12mL Injection
Lack of Assurance of Sterility
Class III · Low risk
Verapamil Hydrochloride Extended-Release tablets
Failed Dissolution Specification: One lot of product did not meet the first stage dissolution specification limits.
Class II · Moderate risk
Verapamil HCl 15% Topical Cream
Lack of Assurance of Sterility and Stability Data does not Support Expiry: recent inspection observations associated with certain quality control procedures that present a risk to sterility and quality assurance.
Class II · Moderate risk
Verapamil HCL
Labeling: Label Mixup: VERAPAMIL HCL, Tablet, 40 mg may have potentially been mislabeled as one of the following drugs: ATORVASTATIN CALCIUM, Tablet, 10 mg, NDC 00378201577, Pedigree: W003095, EXP: 6/12/2014; TACROLIMUS, Capsule, 1 mg, NDC 00781210301, Pedigree: W003352, EXP: 3/31/2014.
Class II · Moderate risk
Verapamil HCL ER
Labeling: Label Mixup: VERAPAMIL HCL ER, Capsule, 240 mg may have potentially been mislabeled as the following drug: FEBUXOSTAT, Tablet, 40 mg, NDC 64764091830, Pedigree: W002664, EXP: 6/5/2014.
Class II · Moderate risk
Verapamil HCL ER
Labeling:Label Mixup; VERAPAMIL HCL ER, Tablet, 240 mg may be potentially mislabeled as TRIFLUOPERAZINE HCL, Tablet, 1 mg, NDC 00781103001, Pedigree: AD52778_91, EXP: 5/21/2014.
Class II · Moderate risk
Verapamil Injection
Lack of Assurance of Sterility; FDA inspectional findings resulted in concerns associated with quality control procedures that impacted sterility assurance
Class II · Moderate risk
Verapamil HCL 10mg/Ml Injectable 80 Ml
Lack of Assurance of Sterility: Franck's Lab Inc. initiated a recall of all Sterile Human Drugs distributed between 11/21/2011 and 05/21/2012. FDA environmental sampling revealed the presence of microorganisms and fungal growth in the clean room where sterile products were prepared.
Free recall alerts
Know the day your medication is recalled
Tell us what you take. When FDA posts a recall announcement or classifies a recall for one of your medications, we email you in plain English, with what to check. No account needed.